Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Orion Oyj
  6. Summary
    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Helsinki
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
37.99(c) 37.76(c) 37.24(c) 37.11(c) 37.17 Last
342 315 326 980 793 376 211 301 12 311 Volume
+0.26% -0.61% -1.38% -0.35% +0.16% Change
More quotes
Financials
Sales 2021 1 053 M 1 254 M 1 254 M
Net income 2021 190 M 226 M 226 M
Net cash position 2021 167 M 198 M 198 M
P/E ratio 2021 27,5x
Yield 2021 3,95%
Sales 2022 1 080 M 1 285 M 1 285 M
Net income 2022 213 M 254 M 254 M
Net cash position 2022 154 M 183 M 183 M
P/E ratio 2022 24,5x
Yield 2022 4,09%
Capitalization 5 216 M 6 214 M 6 208 M
EV / Sales 2021 4,79x
EV / Sales 2022 4,69x
Nbr of Employees 3 344
Free-Float 88,4%
More Financials
Company
Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases. 
Sector
Pharmaceuticals
Calendar
07/19Earnings Release
More about the company
Ratings of Orion Oyj
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ORION OYJ
06/21ORION OYJ  : Animal Health's Dog Anxiety Therapy Wins EU Committee's Positive Op..
MT
06/21ORION OYJ  : Animal Health's Tessie® (tasipimidine) receives positive CVMP opini..
AQ
06/17ORION CORPORATION : Disclosure Under Chapter 9 Section 10 of the Securities Mark..
AQ
06/09ORION OYJ  : Shares Positive Result Of Virtual Reality Therapy DTxP
MT
06/09ORION OYJ  : Clinical Trial Shows Significant Improvement for Chronic Pain Patie..
AQ
06/08ORION OYJ  : Teams Up With Finnish Red Cross Blood Service to Develop Cell Thera..
MT
06/08ORION OYJ  : and the Blood Service launch collaboration to develop new CAR T-cel..
AQ
05/27ORION CORPORATION : Disclosure Under Chapter 9 Section 10 of the Securities Mark..
AQ
05/26ORION OYJ  : Virtual Capital Markets Day today at 13.00 EEST – presentatio..
AQ
05/25ORION OYJ  : Mulls Sale of Pharmaceutical Manufacturing Site in Finland
MT
05/25ORION OYJ  : to investigate possible sale of its pharmaceutical manufacturing pl..
AQ
05/19ORION CORPORATION : Disclosure Under Chapter 9 Section 10 of the Securities Mark..
PU
05/17ORION CORPORATION : Disclosure Under Chapter 9 Section 10 of the Securities Mark..
AQ
05/17ORION OYJ  : Animal Health Lands Positive Opinion From European Medicines Agency..
MT
05/17ORION OYJ  : Animal Health's Bonqat® (pregabalin) receives positive CVMP opinion
AQ
More news
News in other languages on ORION OYJ
02/2540 femmes d’affaires qui comptent en Europe
2020Les actions hésitantes, la Chine et les résultats en soutien
2019AVIS D'ANALYSTES DU JOUR  : Natixis, BNP Paribas, Kering, Coface, Haulotte, Maer..
2019ORION OYJ  : Jefferies fait plier le titre
2019AVIS D'ANALYSTES DU JOUR  : LVMH, Hermès, Kering, Faurecia, STMicroelectronics, ..
More news
Analyst Recommendations on ORION OYJ
More recommendations
Chart ORION OYJ
Duration : Period :
Orion Oyj Technical Analysis Chart | ORNBV | FI0009014377 | MarketScreener
Technical analysis trends ORION OYJ
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 33,94 €
Last Close Price 37,11 €
Spread / Highest target 7,79%
Spread / Average Target -8,54%
Spread / Lowest Target -24,5%
EPS Revisions
Managers and Directors
NameTitle
Timo Antero Lappalainen President & Chief Executive Officer
Jari Ilmari Karlson Chief Financial Officer & SVP-Animal Health
Sinikka Markkula Chief Information Officer
Minna Ruotsalainen Senior Vice President-Research & Development
Paula Rytilä Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ORION OYJ-1.12%6 214
JOHNSON & JOHNSON4.10%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.09%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.07%202 639